Definium Therapeutics' stock surged 6.34% in pre-market trading on Tuesday, continuing the strong momentum in psychedelic-focused biotech stocks.

The rally was triggered by President Donald Trump's executive order signed over the weekend, which directs health regulators to accelerate reviews of psychedelic drugs and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.

Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline, with Phase 3 data readouts expected later this year.